Abstract
Since Antibody-drug Conjugates (ADC) are already approved for the treatment of relapsed Hodgkin’s lymphoma, HER2-positive metastatic breast cancer and B cell lymphoma, among others, high expectations are placed on this class of bioconjugates. Indeed, more than 100 different ADCs have been studied for various applications by 2022, presumably with several more to follow. Due to their composition, however, advanced risk management is necessary during ADC manufacturing, processing and transport. With a monoclonal antibody, a cytotoxic payload and a linker being their three main constituents, individual characteristics and risks of these three components have to be considered. In particular, but not limited to, cytotoxic payloads present unique challenges and pose considerable risks at multiple levels. Therefore, end-to-end solutions for bioconjugation processing are playing an increasing role in ADC processing and the task to cope with these challenges and provide a safe way to make the unique advantages of antibody-drug conjugates more accessible.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
